DNA methylation-regulated miR-155-5p depresses sensitivity of esophageal carcinoma cells to radiation and multiple chemotherapeutic drugs via suppression of MAP3K10

WENGUIANG LUO1,2*, HUANHUAN ZHANG3*, XUE LIANG4,5, RAN XIA3, HUI DENG3, QIYI YI6, LEI LV3 and LITING QIAN5

1School of Medicine, Shandong University, Jinan, Shandong 250100; 2Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001; 3Department of Cancer Epigenetics Program, Anhui Provincial Cancer Hospital, West Branch of The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230031; 4Xinxiang Medical University, Xinxiang, Henan 453003; 5Department of Radiation Oncology, Anhui Provincial Cancer Hospital, West Branch of The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; 6Department of Nuclear Medicine, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230031, P.R. China

Received August 8, 2019; Accepted January 24, 2020

DOI: 10.3892/or.2020.7535

Abstract. Radiotherapy and chemotherapy are two major treatment options for esophageal carcinoma, and heterogeneous treatment effects are observed in the clinical setting to provide an overall 5-year survival rate of ~20%. Hence, defining the molecular mechanisms that affect the chemoradiotherapy response is vital to achieve an optimal outcome. The present study revealed that miR-155-5p may be involved in esophageal squamous cell carcinoma (ESCC). By means of reverse transcription-PCR, the present study defined its differential expression pattern in six ESCC cell lines that were associated with resistance to radiation. Ectopic expression of miR-155-5p promoted DNA damage repair and induced resistance against radiation by non-homologous end joining repair. It also enhanced chemoresistance, proliferation, and migration and invasion of ESCC cells. By further screening its potential target genes, the present study identified MAP3K10 as the direct target gene to exert its anti-chemoradiation functions. The results also demonstrated that its differential expression pattern was negatively regulated by the methylation status of the upstream CpG island. Overall, the results of the present study demonstrated that miR-155-5p is a key molecule for understanding the heterogeneous responses of ESCC to chemoradiotherapy, and may be used in personalized treatment plans for this high mortality tumor in the future.

Introduction

Esophageal cancer is ranked as the ninth most commonly diagnosed cancer and the sixth leading cause of cancer-associated mortality worldwide, with an estimated 572,034 new cases (3.2% of the total) and 508,585 deaths (5.3% of the total) in 2018 (1). It has two main subtypes: Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which are epidemiologically and biologically different. Although EAC is more common in the USA and several countries across Europe, ESCC is the predominant histology subtype of esophageal cancer globally, and occupies >80% of cases of esophageal cancer (2). Currently, surgery is the definitive treatment method for early stage esophageal cancer. For those patients with advanced/unresectable tumors, neoadjuvant chemoradiotherapy has become the standard treatment option (3,4). Even for those early stage patients, pre/post-operative chemoradiotherapy is also widely practiced in the clinical setting. Although some promising outcomes have been observed in clinic trials with neoadjuvant or adjuvant therapy (5-7), the overall 5-year survival of this disease still ranges from 15 to 25% (4), and resistance to chemoradiotherapy is one of the primary reasons for this. Thus, an
improved understanding of the molecular mechanisms that affect tumor cell sensitivity to radiotherapy and chemotherapy would be beneficial for future personalized treatment plans to improve patient survival.

MicroRNAs (miRNAs/miRs) are a class of small noncoding RNAs that regulate gene expression at the post-transcriptional level, and play important roles in various biological processes, including the development of diseases (8). One of the most important tumor-promoting miRNAs is miR-155, which is processed from the B cell integration cluster (9). It has been revealed that aberrant expression of miR-155-5p presents as an oncogenic feature in several types of hematological malignancies and solid tumors (10-14), including ESCC (15,16). It could promote cell proliferation, inhibit apoptosis, and induce EMT, invasion and migration, tumor metastasis and recurrence (17-19). Meta-analyses have demonstrated that miR-155 could be a potential biomarker for lung cancer detection (20), and the combined detection of multiple miRNA levels in ESCC tissues have significant prognostic values (21). However, conflicting studies have been published regarding the role of its dysregulation in radio- and chemo-resistance. For example, interference of miR-155-5p caused resistance to chemotherapy drugs and ionizing radiation in parental human epithoid carcinoma cells (22) and breast cancer (23), respectively. However, the opposite behaviors have also been observed, indicating a greatly increased sensitivity to chemotherapy drugs (11,24) and radiation (25).

Given that there has been little data on the potential role of miR-155-5p in the radio- and chemo-resistance of ESCC cells, the present study determined the endogenous miR-155-5p expression levels and chemoradio-resistance profiles in ESCC cell lines. The results revealed that miR-155-5p was positively correlated with radio- and chemo-resistance. A systematic analysis was subsequently performed in order to reveal its role in response to radiation and drugs, and the underlying mechanism. The data generated in the present study are helpful for finding effective targets for ESCC chemo-radio sensitization.

**Materials and methods**

*Cell culture and transfection.* The human esophageal squamous cancer cell lines (KYSE-30, KYSE-140, KYSE-410, KYSE-450, KYSE-510 and TE-1), which were kindly provided by Professor Zhan (National Laboratory of Molecular Oncology), were cultured in RPMI-1640 medium plus 10% fetal bovine serum (cat. no. 10099-141; Thermo Fischer Scientific, Inc.) at 37°C in 5% CO2. All cell lines were genetically authenticated using STR profiling by Genesky Biotechnologies, Inc.

*Mimic/antagomiR/siRNA/plasmid DNA transfection.* All mimics, antagoniM, siRNA, and the scramble sequence control (NC), as well as riboFECT CP transfection kit (cat. no. C10511-05) were obtained from Guangzhou Ribobio Co., Ltd. Briefly, 4x105 cells were seeded into each well of 6-well plates and cultured overnight, and then they were transfected with 50 nM mimic/siRNA, or 100 nM antagonim using a riboFECT CP transfection kit. A total of 1.2 µg of the GFP-tagged overexpression MAP3K10 construct (cat. no. HBLV-MAP3K10-GFP, Hanbio Biotechnology Co., Ltd.) was transfected into KYSE-410 cells using Attractene transfection reagent (cat no. 301005; Qiagen) according to the manufacturer's instructions. All transfections were carried out at room temperature, after which cells were cultured at 37°C for 24 h. Then they were seeded into 96-well or 6-well plates and underwent subsequent analysis 24 h later.

The siRNA sequences used for MAP3K10 interference in the present study were as follows (5’-3’): CCUGGAAAUCUGG UCUCUUdIdTdT and dTdTGGACCUUUGACCAGGAA.

**Clonogenic survival assay for radiation.** ESCC cells in the exponential growth phase were seeded at a density of 250 (0 Gy), 500 (1 Gy), 1,000 (2 Gy), 2,000 (4 Gy), 4,000 (6 Gy) cells/well on six-well plates in triplicate. After 24 h of incubation, adhesive cells were exposed to a 6 MV X-ray in CX-SN5340 (VARIAN) at 0 Gy, 1 Gy, 2 Gy, 4 Gy and 6 Gy with an average dose rate of 300 cGy/min. After incubation for an additional 14 days, the cultures were fixed in methanol and stained with crystal violet. The number of colonies containing >50 cells were counted under a light microscope. The surviving fraction was calculated as previously described (26).

**Chemosensitivity profiling (IC50 determination).** Vinorelbine (Changchun Guoao Pharmaceutical Co., Ltd.), paclitaxel (Sichuan Taiji Pharmaceutical Co., Ltd.), docetaxel (Jianguo Aokangsi Pharmaceutical Co., Ltd.), 5-flurorocil (Tianjin Jinyao Pharmaceutical Co., Ltd.), mitomycin (Zhejiang Haizheng Pharmaceutical Co., Ltd.), nedaplatin (Jianguo Aokangsi Pharmaceutical Co., Ltd.) and cisplatin (Jianguo Haosen Pharmaceutical Co., Ltd.) at the clinical-grade (NCI Dictionary of Cancer Terms, http://www.cancer.gov/dictionary) were used in the present study. Chemosensitivity profiling (IC50 measurements): Cells in the logarithmic growth phase were seeded in triplicate in 96-well plates at a density of 5x103/well and treated with 4-fold serially diluted drugs for 72 h. Cell survival was then measured using a Cell Counting Kit-8-based (CCK-8; cat. no. B34302; Bimake) cell proliferation assay. The IC50 (the concentration of drug required for 50% of the cells to be killed) was calculated with the no-drug control as the reference.

**Cell proliferation assay.** Cells in the logarithmic growth phase were seeded in 96-well plates at a cell density of 2x104/well (in triplicate) to allow adhesion. At 0, 24, 48, 72 and 96 h, cells were incubated with 10 µl CCK-8 at 37°C for an extra 2 h. The optical density was then measured with a microplate reader (Tecan Group Ltd.) at 450 nm. The cells were then cultured with fresh medium until the next round of measurements. The mean and standard deviation of the triplet measurements were calculated and plotted.

**Wound-healing assay.** Confluent cells were serum-starved in RPMI-1640 medium for 10-12 h and scratched using the tip of a 10-µl pipette. After being washed twice with PBS to remove non-adherent cells, the plates were changed to 500 µl RPMI-1640 medium plus 10% FBS. The wound area was photographed at 0 and 22 h under an Olympus IX73 inverted microscope. A cell-free region was drawn and measured by CellSens Standard software (Olympus). The average and
standard deviation were calculated from no less than three different wounds from one of three attempts.

**Invasion assay.** A BioCoat™ Matrigel invasion chamber (cat. no. 40480; BD Biosciences) was used according to the manufacturer's protocol. Briefly, 4x10⁵ cells were trypsinized, washed, suspended in 200 µl serum-free RPMI-1640 medium, and seeded in the upper portion of the invasion chamber. The lower portion of the chamber contained 500 µl of RPMI-1640 medium plus 10% FBS, which served as a chemo-attractant. After 36 h, the non-invasive cells were removed from the upper surface of the membrane with a cotton swab. The invasive cells on the lower surface of the membrane were stained with 0.1% crystal violet for 30 min at room temperature, and counted in four separate areas with an inverted microscope.

**miRNA target prediction.** Two miRNA target prediction and functional study databases, TargetScan (http://www.targetscan.org/) and miRDB (http://mirdb.org/), were employed to search for the potential targets of miR-155-5p. The overlapped targets were selected for further validation.

**Luciferase reporter assay.** A full length of the human MAP3K10 3'-UTR region (284 bp) with the miR-155-5p targeting sequence was cloned at the downstream region of the firefly luciferase gene in the pGL3-basic vector (cat. no. E1751; Promega Corporation) to construct pGL3-luc-MAP3K10.

Cells were seeded into 96-well plates at ~1x10⁴ cells/well and transfected with a mixture of 100 ng pGL3-luc-MAP3K10, 10 ng Renilla plus 5 pmol mimic or scrambled control (NC) and probes were listed as follows (5' → 3'): 1st forward, GCC GTC TCG AGG GGA AAT TAC ACC ACG GCC ACC CCC, miR-155-5p forward, TC GGA TAT GTG AAT ATC GTG, reverse, GAG GCC AGT GGA AAG and probe, FAM-ACCAGGCC ACC; U6 forward, CTC GCTTCCG GCACACATA, RT and reverse, CGC TTCA CGA ATTTTGCT GTG and probe. HEX-CCT TGGCAGGGGCAC TG.

**Western blot analysis.** Cells were lysed in a solution of 60 mM Tris-HCl, pH 6.8, 2.00% sodium dodecyl sulfate, 20.00% glycerol, 0.25% bromophenol blue, 1.25% 2-mercaptoethanol and heated at 100°C for 10 min. Protein concentrations were determined using a BCA protein assay kit. After being separated by 10 or 12% SDS-PAGE, the protein (40-50 µg) was transferred to a PVDF membrane (cat. no. IPVH00010; EMD Millipore). The membranes were blocked in 1X PBS buffer containing 5% BSA (cat. no. A1933; Sigma-Aldrich; Merck KGaA) and 0.05% Tween-20 (cat. no. A100777; Sangon Biotech Co., Ltd.) for 1 h at room temperature, and then incubated with the following primary antibodies: γ-H2AX (rabbit anti-human monoclonal; 1:1,000; cat. no. 9718; Cell Signaling Technology, Inc.); H2AX (rabbit anti-human monoclonal; 1:1,000; cat. no. 10856-1-AP); Lamin B1 (rabbit anti-human monoclonal; 1:1,000; cat. no. 12987-1-AP); RAD51 (rabbit anti-human monoclonal; 1:1,000; cat. no. 14961-1-AP); and Ku80 (rabbit anti-human monoclonal; 1:1,000; cat. no. -1-AP; all from ProteinTech Group, Inc.); MAP3K10 (sheep anti-human monoclonal; 1:1,000; cat. no. AF5066; R&D Systems); GADPH (mouse anti-human monoclonal; 1:2,000; cat. no. 60004-1-Ig); and α-tubulin (mouse anti-human monoclonal; 1:2,000; cat. no. 11224-1-AP; both from ProteinTech Group, Inc.) over-night at 4°C. The blots were washed with PBST three times for 10 min each and incubated with secondary antibodies anti-rabbit IgG (1:3,000; cat. no. SA00001-2); and anti-mouse IgG (1:3,000; cat. no. SA00001-1; both from ProteinTech Group, Inc.); and anti-sheep IgG, 1:1,000, cat. no. HAF016, R&D Systems) for 1 h at room temperature. The target bands were revealed by SuperSignal West Pico PLUS chemiluminescence substrate (cat. no. 34580; Thermo Fisher Scientific, Inc.), and the relative density of each protein over Lamin B1, GADPH or α-tubulin was quantified using a Gel-Pro Analyzer 3.1 (Media Cybernetics).

**5-Aza-2'-deoxycytidine treatment.** KYSE-140 and KYSE-30 cells were treated with 50 mM 5-aza-2'-deoxycytidine (5-aza-dC; cat. no. A3656; Sigma-Aldrich; Merck KGaA) for 72 h with a change of culture medium every 24 h as previously described (30).

**BSP analysis.** Genomic DNA was isolated using a PureGenome™ kit (cat. no. P-9040-M; Aline Bioscience) and quantitated via electrophoresis on an agarose gel. The bisulfate conversion was achieved using an EZ DNA Methylation-Gold Kit (cat. no. DS006; ZYMO Research). The CpG Island upstream of miR-155 gene was amplified by two pairs of primers. The sequences of the primers were listed as follows (5' → 3'): 1st forward, GTTGAGTGTTGTTAATGATAGTTAAGTGAG and reverse, CAA AAA ACR TCT CTT AAT TCC CT; 2nd forward AAGGAGAYGTTTTTTGATTTTGTAG and reverse, GAC ACC TAA TAC CCCC AAA AAC. Briefly, 500 nM of each primer, 4 mM dNTP, 2 mM MgCl₂, 6.25 U Hotstart Taq DNA

**Reverse transcription-quantitative PCR (RT-qPCR).** Total RNA was isolated from the cells at the logarithmic growth phase using TRNzol-A+ reagent (cat. no. DP421; Tiangen Biotech Co., Ltd.), and 1 µg RNA was converted to cDNA with a 100-nM mixture of miR-155 specific stem-loop primer and U6 specific reverse primers (synthesized by ShingGene) using the HiScript II 1st Strand cDNA Synthesis kit (cat. no. E1751; Promega Corporation) to construct pGL3-luc-MAP3K10.

Total RNA was isolated from the cells at the logarithmic growth phase using TRNzol-A+ reagent (cat. no. DP421; Tian gen Biotech Co., Ltd.), and 1 µg RNA was converted to cDNA with a 100-nM mixture of miR-155 specific stem-loop primer and U6 specific reverse primers (synthesized by ShingGene) using the HiScript II 1st Strand cDNA Synthesis kit (cat. no. E1751; Promega Corporation) to construct pGL3-luc-MAP3K10.
polymerase and 2% DMSO were used for each round of PCR. The conditions used were as follows: 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, and 60°C for 1 min. The PCR fragments from the converted DNA were cloned and verified by sequencing as previously described (31).

Online data for gene expression in esophageal cancer. A ESCC cohort from The Cancer Genome Atlas (TCGA) was included for survival rate analysis using Kaplan-Meier survival analysis. Oncomine database (https://www.oncomine.org/resource/login.html) was used to mine the data of MAP3K10 gene expression in ESCC and EAC.

Statistical analysis. Data are presented as the means, and error bars indicate the standard deviation (SD). All statistical analyses were performed with Excel (Microsoft, Inc.) or GraphPad Prism 6 (GraphPad Software Inc.). One-way ANOVA followed by Dunnett's post hoc test and two-tailed Student's t-test were used to calculate statistical significance. A P-value of <0.05 was considered to indicate a statistically significant difference.

Results

miR-155-5p is differentially expressed in ESCC cells and positively associated with radioresistance. The expression level of miR-155-5p was examined in six ESCC cell lines via RT-qPCR (Fig. 1A). The results revealed that the expression of miR-155-5p varied among the different cells, with KYSE-410 cell expression ~55.3-fold higher than KYSE-140 cells. As radiotherapy is widely applied to patients with ESCC and has a central role in the therapeutic strategy against ESCC, the sensitivity of six ESCC cell lines to radiation was then evaluated using a clonogenic survival assay (Fig. 1B). The surviving fraction of KYSE-410 cells was greater than that of the other five cell lines, indicating that KYSE-410 was the most radioresistant, whereas, KYSE-30 and KYSE-140 presented with the highest radiosensitivity. These indicated a positive association between radioresistant capacity and the expression of miR-155-5p in ESCC cells. Thus, KYSE-140 (the most radiosensitive cells whose miR-155 was the lowest) and KYSE-410 (the most radioresistant cells whose miR-155 is the highest) were selected cell lines for the following study.

miR-155-5p renders ESCC cells resistant to radiation by repairing the DNA damage more efficiently. In order to investigate the role of miR-155-5p in the radiotherapy response of ESCC cells, the present study ectopically expressed miR-155-5p and the corresponding control scrambled RNA in radiosensitive KYSE-140 cells, which were then irradiated after seeding on cell culture plates for clonogenic survival assays. Following overexpression of miR-155-5p to >300-fold (Fig. 2A), the survival rate of the mimic-transfected KYSE-140 cells at each dose was higher than that of NC (Fig. 2C), indicating that miR-155-5p enhanced radioresistance. Conversely, silencing of miR-155-5p to 20% in KYSE-410 cells (Fig. 2B) decreased the cell survival rate against radiation (Fig. 2D), indicating that inhibition of miR-155 sensitized ESCC cells to radiation.

It has previously been proposed that ionizing radiation damages tumor cells through several mechanisms, mainly by DNA damage, particularly double-strand breaks (DSBs) (32,33). Cell survival following DNA damage relies on DNA repair, the abrogation of which causes genomic instability and cell death. In order to confirm that a defect in the repair of DSBs is involved in the radioresistance mediated by miR-155-5p in ESCC cells, cells were exposed to X-rays at 4 Gy in the present study. The expression level of phosphorylated histone family member X (γ-H2AX), which is a powerful biomarker to monitor DSBs in cells (34), was detected at various time-points after radiation. Significant induction of γ-H2AX was observed at 0.5 h after radiation compared to the cells without radiation. It decreased more rapidly from 6 h post-radiation in miR-155-5p overexpressing-KYSE-140 cells, compared to the NC group. Conversely, the level of γ-H2AX
decreased more slowly in the anti-miR-155-5p KYSE-410 cells from 6 h after radiation, compared to the NC group (Fig. 2E-G). This revealed that there was an early onset and high capacity of DNA repair by upregulation of miR-155-5p.

DSB induced in mammalian cells is repaired by two repair pathways. One is non-homologous end joining (NHEJ), the other is homologous recombination (HR). Deficiency in proteins involved in the DNA damage repair is considered a major determinant of response to radiotherapy and chemotherapy (35). Thus, the present study investigated whether increased expression and/or activity of DNA repair proteins confer resistance to radiation. The protein levels of RAD51 and Ku80, the key components of HR and NHEJ, respectively, were examined. The results revealed the expression of Ku80 was increased from 0.5 h after radiation in the miR-155-5p mimic-transfected KYSE-140 cells, but it remained almost
unchanged in the NC group. Consistently, accumulation of Ku80 occurred at 0.5 h after radiation in KYSE-410 cells, but its level was significantly lower in anti-miR-155 KYSE-140 cells compared to the NC group (Fig. 2E-G). Thus, NHEJ rather than HR played a major role in repairing the DSB induced by radiation in ESCC cells. Collectively, miR-155-5p promoted DNA damage repair and induced resistance against radiation via upregulation of Ku80 and activation of NHEJ repair.

**Increased expression of miR-155-5p promotes multi-drug resistance in ESCC cells.** Generally, resistance occurs not only to radiation but also to traditional chemotherapeutic drugs in cancer cells. Thus, the present study performed drug-resistance profiling in two cell lines against the following drugs: Paclitaxel, docetaxel, vinorelbine, cisplatin, nedaplatin, mitomycin and 5-fluorouracil. The dose required for the IC_{50} after a treatment of 72 h was determined. In agreement with the radio-resistance profiles, KYSE-410 cells were more resistant to multi-drugs than KYSE-140 cells (Fig. 3A), which indicated that miR-155-5p was also involved in the chemo-resistance of ESCC cells. 

In order to demonstrate its role in the ESCC chemoresistance, the present study examined the drug-induced cell death in mimic/antagomiR-transfected cells. The results revealed that introducing miR-155-5p increased the cell viability of KYSE-140 cells after treatment with vinorelbine, cisplatin, paclitaxel and docetaxel (Fig. 3B). Conversely, knockdown of miR-155-5p sensitized KYSE-410 cells to 5-fluorouracil, vinorelbine, cisplatin and docetaxel (Fig. 3C). Therefore, miR-155-5p enhanced ESCC cell resistance to vinorelbine, cisplatin and docetaxel in a drug-specific manner.

**miR-155 enhances migration, invasion and proliferation of ESCC cells.** The present study further investigated whether miR-155-5p interfered with the potential motility and proliferation of ESCC cells. A marked positive correlation between the expression of miR-155-5p and the motility of ESCC cells was observed. Following overexpression of miR-155, KYSE-140 cells migrated 1.8-fold faster than the control groups (Fig. 4A and B). In contrast, miR-155-5p downregulation decreased the migratory speeds of KYSE-410 cells by ~50% (Fig. 4A and B). Additionally, the number of invaded cells were increased in the miR-155-5p-overexpressing KYSE-140 cells and decreased in anti-miR-155-5p KYSE-410 cells (Fig. 4C and D), confirming the promoting role of miR-155-5p in motility. Furthermore, the present study demonstrated that the proliferation, quantified by a CCK-8 assay over a period of 4 days, was increased in mimic-transfected KYSE-140 cells (Fig. 4E) and decreased in antagonir-transfected KYSE-410 cells compared with the control groups (Fig. 4F). All these data indicated that in addition to radio- and chemo-resistance, miR-155-5p also contributed to high migration and invasion capacities and an increased proliferation rate in ESCC cells, confirming the oncomiR role of miR-155-5p. Consistently, by analyzing the survival rate of a ESCC cohort form TCGA, we found that high expression of miR-155-5p was associated with poor overall survival in patients with ESCC (Fig. S1).

**DNA methylation around the transcription start site of miR-155HG exhibits differences in ESCC cell lines and is negatively correlated with the expression of miR-155.** miR-155 is encoded by the non-protein-coding BIC gene (now designated, MIR155 host gene or MIR155HG). MIR155HG promoter sequence and the first exon harbor a CpG island (CGI) containing 51 CpGs (Fig. 5A). In order to elucidate the mechanisms implicated in the regulation of miR-155 expression, the present study hypothesized that the DNA methylation
status of CpGs, which is the best-characterized epigenetic mechanism (36), may be involved in the regulation of miR-155 expression levels. A bisulfite conversion sequencing (BSP) analysis of this region was performed. Two pairs of primers were used to amplify the 45 CpG sites in the CGI. The results revealed that DNA methylation differed among the six cell lines. CGI was hypermethylated in KYSE-140 and KYSE-30 cells, moderately methylated in KYSE-510 and TE-1 cells, but barely methylated in KYSE-410 and KYSE-450 cells (Fig. 5B and C). To further confirm the transcriptional repression of miR-155 by DNA methylation, the methylase inhibitor 5-aza-dC was used in the present study. After treatment with 5-aza-dC, the expression of miR-155-5p was increased by >3-fold in the KYSE-140 and KYSE-30 cells (Fig. 5D). In addition, evaluation of DNA methylation status revealed that the two cell lines exhibited a partially demethylated pattern in the CpG island upstream of the miR-155 gene (Fig. 5E). In conclusion, the transcription of miR-155 gene was repressed by DNA methylation of the MIR155HG promoter.

MAP3K10 is the target gene of miR-155 in ESCC cells. The present study assessed the level of overlapped predicted target genes of miR-155-5p in the Arraystar datasets (data not shown) of KYSE-140 and KYSE-410 cells. MAP3K10 was observed to be expressed in an opposite manner to miR-155-5p. Further RT-qPCR and western blot analyses demonstrated that the protein level of MAP3K10 was significantly higher in the KYSE-140 than that in the KYSE-410 cells (western blot analysis, 1.00:0.51; Fig. 6A). Furthermore, miR-155-5p mimic transfection decreased the levels of MAP3K10 by ~60% in
KYSE-140 cells, and its level was increased by ~2.3-fold in the antagomiR-transfected KYSE-410 cells (Fig. 6B).

For confirmation that MAP3K10 is the direct target of miR-155-5p, its 3'-UTR regions were placed downstream of the firefly luciferase gene in pGL3 (Promega Corporation) to create the pGL3-MAP3K10 UTR construct (Fig. 6C). Both pGL3-MAP3K10 UTR and pGL3 were transfected into KYSE-140 and KYSE-410 cells, in order to observe the functional state of miR-155-5p in these cells. pGL3-MAP3K10-UTR, but not pGL3, produced a 1.5-fold higher luciferase activity in KYSE-140 than in KYSE-410 cells, in an opposite pattern of miR-155-5p expression (Fig. 6D). Furthermore, the luciferase activity of pGL3-MAP3K10-UTR WT was decreased by 45% in the mimic-transfected KYSE-140 cells (Fig. 6E) and increased by 50% in the antagomiR-transfected KYSE-410 cells, but not in the pGL3-transfected control (Fig. 6F). Collectively, MAP3K10 is in fact a direct target of miR-155-5p and may execute its effect on ESCC radio- and chemo-resistance.

MAP3K10 suppresses radio- and chemo-resistance of ESCC. In order to investigate the role of MAP3K10, siRNA transfection-mediated knockdown of MAP3K10 was performed in KYSE-140 cells in the present study. The expression of MAP3K10 was decreased to 28% by siRNA at the protein level (Fig. 7A). Suppression of MAP3K10 not only increased the cell viability when compared with the control groups after exposure to radiation (Fig. 7B), but also significantly desensitized KYSE-140 cells to the cell death triggered by vinorelbine and cisplatin (Fig. 7C). Conversely, overexpression of MAP3K10 in KYSE-410 cells (Fig. 7D) decreased resistance against radiation (Fig. 7E) and drugs (Fig. 7F). In contrast to the effect imposed by the miR-155a-5p mimic, both MAP3K10 knockdown and overexpression failed to cause a significant change of sensitivity to docetaxel, which indicated that other target genes of miR-155-5p may participate in this process.

Furthermore, the present study also observed that the proliferation of ESCC cells was suppressed by MAP3K10.
However, migration speed and invasion capacity were not influenced by forced reversal of MAP3K10 (Fig. S2A-D), indicating that the miR-155-5p regulated the motility of ESCC cells via other target genes. Additionally, MAP3K10 was revealed to be slightly downregulated in ESCC tumor samples but significantly upregulated in esophageal adenocarcinoma (EAC) compared with normal tissues based on Oncomine database (Fig. S3), which indicated that it may not contribute to tumorigenesis in ESCC as that in EAC, but induced chemoradio-resistance in ESCC.

MAP3K10 is a member of the serine/threonine kinase family, which preferentially activates the C-Jun N-terminal kinase (JNK) signaling pathway (37). The present study examined the JNK pathway activity by Qiagen™ pathway reporter assay and revealed that it was ~5-fold higher in KYSE-140 cells than in KYSE-410 cells (Fig. 7G). Furthermore, suppression of MAP3K10 by siRNA or mimic transfection decreased the JNK signaling activity by ~50% in KYSE-140 cells (Fig. 7H). Conversely, the activity was upregulated by >1.4-fold in antagomiR- and MAP3K10-GFP-transfected KYSE-410 cells (Fig. 7I). Therefore, MAP3K10 mediated the promoting effect of miR-155 on resistance against both radiation and drug treatment in ESCC cells, via its effect on the JNK signaling pathway.

**Discussion**

The overall prognosis for ESCC is poor, due to diagnosis at advanced stages of disease, high incidences of tumor recurrence and metastasis, and the insensitivity to radiotherapy and chemotherapy. Several clinical trials have demonstrated that
LUO et al.: miR‑155‑5p PROMOTES CHEMORADIO‑RESISTANCE IN ESCC

The response to chemoradiation is crucial for the prognosis of patients (5‑7); thus, finding molecular markers that can predict the benefits of chemoradiotherapy for patients with ESCC can prevent discomfort and toxicity. The present study demonstrated that miR‑155‑5p expression under the negative control of DNA methylation conferred ESCC cell resistance against both radiation and chemotherapy drugs in vitro, in agreement with the in vivo data that high expression of miR‑155 in patients with ESCC revealed a worse prognosis than those with low expression (38). Consistent with its status as an oncomiR in other tumors (39‑41), it was also revealed that miR‑155‑5p could enhance proliferation, migration and invasion of ESCC cells. In addition, it has been previously reported that miR‑155 promotes cancer progression via inhibition of apoptosis, inducement of EMT and metastasis, and increased risk for recurrence (17‑19).

It has been proposed that repair of DNA damage is essential for the maintenance of genomic stability and tumor cell survival following radiation (33). In the present study, it was revealed that miR‑155‑5p accelerated DNA damage repair,
and NHEJ was the major repair pathway for DSBs in ESCC that was responsible for the high efficient DNA repair. As anticipated, enhanced DNA damage repair capacity led to resistance to radiation. These results are consistent with the viewpoint that NHEJ acts during any phase of the cell cycle and is the primary mechanism for the repair of DSBs induced by radiation (42); however, this is contrary to a study on breast cancer in which it was revealed that miR-155-5p decreased the efficiency of homologous recombination repair and enhanced sensitivity to radiation by targeting RAD51 directly (23). The present study demonstrated that the expression of RAD51 was not down-/up-regulated in the miR-155-5p mimic/antagomir-transfected cells. This may be due to the different interactions of miRNA-mRNAs in different types of cancer (43). Thus, miR-155-5p binds to other target genes in ESCC and promotes chemoradio-resistance. Given that the level of Ku80 changed only when radiation occurred in the present study, it was supposed that Ku80 is indirectly regulated by miR-155-5p through other mediators after radiation. Further investigations are required in order to confirm the association between Ku80 and miR-155-5p.

Radiosensitivity may occur simultaneously with chemoresistance in patients with cancer (44). In fact, in the present study, miR-155-5p also enhanced chemoresistance, and this impact was drug type-specific. The intrinsic response of cancer cells to chemotherapy drugs may be different due to the different drug properties. First, the anticancer effect of chemotherapeutic drugs was achieved through various mechanisms. For example, cisplatin induces covalent crosslinks between DNA bases, interferes with DNA repair mechanisms and causes DNA damage and subsequently apoptosis in cancer cells (45). Docetaxel not only inhibits depolymerization of microtubules, but also induces apoptosis by binding to Bcl-2 or Bcl-xL and thus arresting the function of each (46). Second, unlike the target therapeutics, the pathways challenged by the conventional chemotherapeutics remain unclear. It has previously been reported that different drugs affect specific signaling pathways in tumor cells, and thus the response of these pathways to drugs was revealed to be both cell type- and drug type-specific (47). Furthermore, it was revealed that certain drugs such as 5-fluorouracil had no effect on miR-155-5p mimic, but had an effect on antagomir. It is proposed that the signaling pathways involved in 5-fluorouracil transport and metabolism may be mutant or defective in KYSE‑140 cells. In this case, forced reversion of miR-155-5p may not help to change the cell survival rate under 5-fluorouracil treatment. It is a question worth further investigation. Therefore, miR-155-5p induced resistance to docetaxel, cisplatin and vinorelbine in ESCC cells, potentially by involving certain signaling pathways.

A miRNA executes its biological function via repression in a sequence-specific manner of up to ~2,000 protein-coding genes at both stability and translation levels of mRNAs. The present study defined the role of MAP3K10, the direct target of miR-155-5p and relayed the impact of miR-155-5p on the ESCC radio- and chemo-resistance through regulation of JNK pathway activity. A previous study revealed that knockdown of MAP3K10 sensitized pancreatic cancer cells to gemcitabine (48). However, the opposite was observed in the present study, siRNA-mediated suppression of MAP3K10 enhanced rather than suppressed the multi-chemoresistance and radio-resistance of ESCC cells. The functional disparity in cancer biology of MAP3K10 is likely attributed to the system difference of studies concerning the type of cancer with different expression patterns of MAP3K10. Compared with tumor-adjacent normal tissue, increased MAP3K10 expression was observed in pancreatic ductal adenocarcinoma (PDAC) tissues and cells (48). However, it was observed to be slightly downregulated in ESCC tumor samples following a hierarchical clustering analysis of gene expression through the Oncomine database and gene microarray data analysis (49). In another study, genome-wide gene expression profiling revealed that MAP3K10 was significantly upregulated in esophageal adenocarcinoma (EAC) compared with normal tissues when assessing with DNA microarray technology (50). As mutations in MAP3K10 are rare in esophageal cancer, according to TCGA analysis, it is proposed that the epigenetic modification of MAP3K10 at the post-transcriptional level may be a crucial factor leading to its misregulation in esophageal cancer. Therefore, these results indicated that MAP3K10 may not participate in tumorigenesis in ESCC such as in PDAC and EAC, but confer sensitivity to radiation and drugs in ESCC.

In summary, the present study revealed that miR-155-5p, whose expression under the control of DNA methylation confers resistance to radiation and chemotherapeutic drugs, enhanced proliferation, migration and invasion, and promoted DNA damage repair by repairing the DSBs more efficiently. MAP3K10 significantly contributed to the positive control of ESCC chemoradio-resistance and proliferation via the JNK pathway. The present study provides a new set of diagnostic targets for the guided personalized chemotherapy of ESCC.

Acknowledgements

We thank Dr Zhang for his help in revising the final manuscript. Special thanks to Professor Zhan from the National Laboratory of Molecular Oncology, for kindly providing the ESCC cell lines.

Funding

The present study was supported by the National Natural Science Foundation of China (81602230, 81502191 and 81402327), and the Anhui Provincial Natural Science Foundation (1508085SMH233, 1508085QH178 and 1508085QH183). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, and in the decision to publish the results.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LL and LQ conceived and designed the study. WL, HZ, XL, RX, HD and QY acquired the data. LL and QY analyzed and
interpreted the data (e.g., statistical analysis, biostatistics, computational analysis). WL, LL and LQ wrote, reviewed, and/or revised the study. All authors read and approved the final manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


